Conference Call Recap: The Verbatim Version The call

New Post Public Reply Private Reply Replies (6) Message Board
Respert24
1,240
Conference Call Recap: The Verbatim Version

The call kicks off with a wonderful discussion concerning forward looking statements and how shit could go sideways or foreways, possibly crossways. Some kind of ways. If you’re like me you’ve recorded this portion to listen to again later when you’re alone, and you’ve also bought puts on foreway options to hedge your bets. Shit, I remember back in my college days when a foreway meant something different. Good times.

Ooh, now we’re into the meat and potatoes now that we’ve gotten the legal stuff out of the way. Good news if you had “restore credibility” on your bingo card 17 times because five minutes into this call it’s been referenced constantly.

How hard would it be to change “to restore credibility within the scientific community” to “to ensure we put forth the strongest scientific case for Leronlimab possible”? Or change “to restore credibility with the FDA” to something like “working hard to make sure that we maximize our interactions with the FDA and provide unassailable data in the formats they require, ensuring we minimize any potential for delays or setbacks on the path to approval”?

For fuck’s sake can we PLEASE shut up about past credibility problems? It’s in the past. It’s time to act like the past shit that wasn’t up to snuff never happened, because at this point it doesn’t matter. What matters is making good, strategic decisions moving forward. This isn’t right and we’re fixing it. Here’s the timeline. This is missing and we’ve identified that. Here’s how we’re going to rectify it and our expected timeline. That program is on track, and here is where we stand.

Management is absolutely trying to do things the right way and bring this ship to port, but every time they start to talk about today or tomorrow they can’t help but frame it with issues from the past. Cut that shit out. It does no good and it’s not necessary. If you fucked up in a relationship right before finding the person you really love, would you preempt every romantic session with the admission that you screwed up a former relationship?

Hey babe, I know we’re about to make love and I’m super excited about it. I mean, I’ve been working on this pinky thing I’m calling “The Jackhammer” that I can’t wait to show you. I’m gonna pair it with that thumb thing I did that one time in Cancun called “The Thumper” and you’re gonna love it. I can’t friggin wait for you to experience it. But before we start I think it’s important for you to know about Stacy. You see, Stacy and I use to date and man oh man did we do some nasty stuff together. There was peanut butter and toys and clamps and industrial sized vats of petroleum jelly. It was some real freaky shit. And I just think it’s important for you to know that things used to get real disgusting with Stacy. Sometimes illegal, if I’m being honest. Hell, I can’t go back to France or I’ll do major time. Thank god for extradition laws. But listen, let me reiterate that I’ve been a real douchebag in the past. I’ve cleaned up my act and as you can see, I’m a pretty fantastic catch now. I just can’t stress enough that I used to be a disaster. DIS-ASS-TER. Now let’s get you out of those clothes…

Now we move on to the Tanya portion of the evening. She assures us that everyone is working hard and the board is holding the company accountable for their strategy and decisions. Then she begins talking about the search for a new CEO and as she rambles on and on it becomes muddy as hell that maybe, just maybe, they’ve hired a new CEO.

A couple hours later she gets to the point, and yes, we have our new CEO.

Except that he’s just the president first. Then, assuming he says “credibility” enough times he’ll earn enough company credits to become CEO. Not sure why that extra designation will take six months before it happens, but if we’re being honest with ourselves, we know exactly why. Cytodyn timelines are like Lucy holding the football for Charlie Brown. Everything can be in place, with the people and the football all positioned for a great attempt at a field goal. But Lucy keeps pulling the ball at the last second, resetting the timeline and expectations. It doesn’t ever get discussed, but Lucy is an asshole. Just let him kick the damn thing for once. He’s a kid who’s already balding. Let him have something, for crying out loud.

Oh! Now it’s time for the Kelly & Recknor show.

It starts off and it has a middle and then it ends.

Alright, alright, I’ll go into more depth.

The good news is that everyone is still optimistic. The bad news is that everything will continue to take even more time than expected. No worries though. Minor stuff. Just gotta work it and rework it and wait longer. Schedule meetings with the FDA and go out to actively seek partners. But in the meanwhile we found out some interesting information on the mechanism of action. Apparently Leronlimab at 350mg (lower dosage) shows different effectiveness and biomarker data than a 700mg (higher) dosage.

Normally you can predict what a higher dose will do. More efficacy is possible. Equal efficacy is another, because at some point you max out the capability of the drug at some particular dose. But rarely do you see it work way better at a lower dose. It reminds me of a drug called Mirapex, which was originally used in Parkinson’s patients at about 2 grams per dose. Later they found that it had a positive effect in patients diagnosed with restless leg syndrome. But the dose they used for that was .125 MILLIGRAMS. That’s a massive difference in dosing. Which also reminds me of a friend who works at Pfizer and many years ago helped me get into a drug study to make some extra cash. He told me that it was safe (it was) but that I should be wary of other studies for experimental drugs because they’d had a study for a drug to treat insomnia that went bad. They picked the wrong starting dose and had really difficult times waking up the participants.

Scary.

Anyway, my point is that it’s pretty interesting that higher/lower doses of Leronlimab might be resulting in significantly different effects on the immune system. Not just stronger or weaker effect, but literally causing different effects and pinging different biomarkers from each other.

Chris Recknor nerds out for ten straight minutes and I follow most of it but immediately forget it.

We’re told at some point that we’ll need to authorize new shares. It might have happened earlier and I just blacked out during that part, but it’s not a good thing. That doesn’t sound like a company about to partner with someone who would/should be giving us gobs of money. Interestingly, we hear none of the same old phrases about companies under NDA and things heating up like we have on every other call. Kelly sounds like we’ve just now decided to get proactive in looking for partnerships. It honestly sounded like we have nothing on the horizon and anything that comes along will be due to our efforts moving forward. I’d be lying if I didn’t say that this part of the call is what made me the most unhappy.

Before you know it we’ve moved on to the question and answer session where, once again, they read lots of questions from idiots who can’t be bothered to do the bare minimum of due diligence. Or questions that were clearly negatively biased. So we’re just going to abandon the BLA for HIV and go bankrupt, huh? Care to comment? Or both of these things in the same question. Are we ever going to find out how the 700mg arm did and when will we run out of money?

Kelly and Miggie put a button on it and the call ends.

If you were to take everything we know about Cytodyn, Leronlimab, and how they’ve communicated to us in the past away, I’d say this call could be looked at positively. New eyes hopefully see the potential.

That being said, I envision a little drop tomorrow. Nothing major. I think the volume this week speaks, well, volumes. We’re no longer the same fertile ground for shorts and day traders because we’re not trading a ton of shares each day anymore. Maybe they’ll roar back when a PR hits, but it seems they’ve moved on. I’m probably wrong about everything, but that’s why the famous phrase “don’t take your stock advice from Respert24” exists.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

MERSCO’s Holiday Push Tests Backyard Play Demand in 2026

Updated Category News Views 103

A trampoline sale is not exactly a macroeconomic bellwether, but it does expose a useful little corner of holiday spending: parents buying big, awkward, discretionary stuff that has to earn its space in the yard. MERSCO is joining Amazon’s Black Friday and Cyber Monday window from November 19 through November 30, 2026, with discounts reaching 38% on selected products....

Continue Reading
Blast Doubles Athabasca Ground, but Drills Still Matter

Updated Category News Views 0

More ground in Athabasca can wake up a uranium junior fast, and Blast Resources has certainly grabbed investors’ attention with this one. The company has optioned eight additional uranium claims beside its Wales Lake property in northern Saskatchewan, taking its regional footprint from 12,150 hectares across 16 claims to 30,732 hectares across 24 claims. That is more...

Continue Reading
PSEG Long Island Warns Customers on QR Payment Scams

Updated Category News Views 131

Holiday panic is a thief's favorite crowbar, and Long Island households are plainly in the crosshairs. PSEG Long Island used Utility Scam Awareness Day on Nov. 18 to warn customers about impersonators demanding immediate payment under threat of a power shutoff. The central message, “Think Before You Scan,” is not flashy corporate wallpaper. It is practical advice for...

Continue Reading
First US Extends Buyback Clock Through Year-End 2027

Updated Category News Views 188

A buyback extension is not a thunderclap; it is a bank board keeping a useful tool within reach. First US Bancshares has pushed the expiration of its existing repurchase authorization from December 31, 2026, to December 31, 2027. That matters, but investors ought to resist turning a calendar change into a grand earnings prophecy. The company has bought back 2,122,972...

Continue Reading
GE Aerospace Backs Service Members With $100K Gift

Updated Category News Views 190

A six-figure commitment can look tiny beside jet-engine budgets, yet it can matter a great deal when it reaches people navigating the awkward jump from military service into civilian life. GE Aerospace has committed $100,000 to Embry-Riddle Aeronautical University to support transitioning service members. That is the whole heart of this announcement, and frankly, it is...

Continue Reading
Aimbient's OR Timestamp Study Puts Efficiency to Test

Updated Category News Views 160

A camera catching a patient’s arrival on time may sound mundane, but operating rooms are where mundane details can turn into serious money and better operational decisions. Aimbient’s newly corrected announcement points to an independently conducted Stanford Medicine study in JAMA Surgery that tested whether its computer-vision system could document key operating-room...

Continue Reading
Automotive Laminates: Small Market, Real EV Leverage

Updated Category News Views 126

Cabin trim has become a surprisingly serious battleground, and that is the whole point of this automotive laminates story. Nobody buys a vehicle because somebody bragged about a multilayer film behind the door panel. Yet the materials under the fingertips, beneath the carpet, and around the dashboard increasingly decide whether an interior feels cheap, quiet, durable, or...

Continue Reading
Early Therapy After Sports Injuries Deserves Careful Timing

Updated Category News Views 27

A limp can become a bad habit long before an athlete calls it one. That is the plain, useful concern behind Dr. Kali Spoto LaRue's discussion of sports-injury physical therapy for athletes in Fairport and Greater Rochester. The central message is not that every sore muscle needs the same response, nor that anybody should charge back into practice because they had one...

Continue Reading
FAA Funding Gridlock Raises Aviation Reliability Risk

Updated Category News Views 8

Friday’s radar and communications trouble delivered the sort of warning nobody in aviation can shrug off: the machinery behind the flight board is getting old, fragile, and far too dependent on people improvising around it. Thousands of flights were delayed or canceled when air traffic control facilities became unstable, according to the Southwest Airlines Pilots...

Continue Reading
Schloss Johannisberg Leads 2026 Global Vineyard List

Updated Category News Views 135

A 1,200-year-old riesling estate just beat the world at being memorable. Schloss Johannisberg in Germany’s Rheingau has taken No. 1 in The 50 Best Vineyards 2026, moving up from No. 2 last year and also claiming Best Vineyard in Europe. For anyone watching the wine business from the outside, this is not really a story about one bottle edging out another. It is a...

Continue Reading

Top 5 Most Recently Viewed Articles

Insightful Disclosure on Rathbones Group and De La Rue Plc

Updated Category News Views 144

Key Public Position Disclosure for Rathbones Group Plc Understanding the dynamics behind stock holding and market behavior is crucial for investors and stakeholders. This article sheds light on the recent public opening position disclosure made by Rathbones Group Plc regarding its interests in De La Rue Plc. According to the regulations of the Takeover Code, disclosers...

Continue Reading
ThinkAndor® Reigns as Leading AI Platform for Virtual Care

Updated Category News Views 132

ThinkAndor® Wins Top Honors in Virtual Care Solutions Andor Health's ThinkAndor® has distinguished itself yet again as the leading **AI healthcare software infrastructure**, confirmed by recent evaluations as the best virtual care platform. This notable recognition by an acclaimed market research assessment underscores the platform's unmatched capabilities in bringing...

Continue Reading
Jayud Global Logistics: Legal Actions and Investment Alerts

Updated Category News Views 165

Understanding the Securities Fraud Class Action Against Jayud The Law Offices of Howard G. Smith have announced a significant legal development involving Jayud Global Logistics Limited (NASDAQ: JYD). A class action lawsuit has been initiated on behalf of investors who purchased Jayud securities. The lawsuit covers shares bought during a specific period, and affected...

Continue Reading
Exploring the Explosive Growth of the 3D Printing Market

Updated Category News Views 101

3D Printing Market Size Analysis As of 2023, the 3D printing market was valued at USD 21.1 billion and is expected to grow to USD 118.9 billion by 2032, reflecting a compound annual growth rate (CAGR) of 21.2% during the forecast period. Current Trends Fueling Growth The 3D printing industry is experiencing remarkable expansion, driven by technological innovations and...

Continue Reading
Nexus Industrial REIT Sells Legacy Properties and Expands Operations

Updated Category News Views 111

Nexus Industrial REIT Emphasizes Focus on Industrial Real Estate Nexus Industrial REIT is creating a buzz in the market with its recent strategic initiatives. The company has officially offloaded a 50% stake in six office buildings, reinforcing its concentration on industrial properties. This transaction signifies a key moment, bolstering Nexus's standing as a prominent...

Continue Reading